HomeLatest ThreadsGreatest ThreadsForums & GroupsMy SubscriptionsMy Posts
DU Home » Latest Threads » Forums & Groups » Topics » Health » Exercise and Fitness (Group) » Has anyone ever dislocate... » Reply #6

Response to Baobab (Reply #5)

Tue Mar 29, 2016, 04:32 PM

6. this may be relevant - no consistent changes at the hip after 16 weeks but generally positive change

https://www.ncbi.nlm.nih.gov/pubmed/25322274


Abstract

Send to:
J Clin Endocrinol Metab. 2014 Dec;99(12):4720-9. doi: 10.1210/jc.2014-2799.

Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial.

Ornstrup MJ1, Harsl°f T, KjŠr TN, Langdahl BL, Pedersen SB.
Author information
Abstract
CONTEXT:

Metabolic syndrome (MetS) is associated with low-grade inflammation, which may harmfully affect bone. Resveratrol (RSV) possesses anti-inflammatory properties, and rodent studies suggest bone protective effects.
OBJECTIVE:

This study sought to evaluate effects of RSV treatment on bone in men with MetS.
SETTING AND DESIGN:

The study was conducted at Aarhus University Hospital as a randomized, double-blinded, placebo-controlled trial assessing changes in bone turnover markers, bone mineral density (BMD), and geometry.
PARTICIPANTS:

The study population comprised 74 middle-aged obese men with MetS recruited from the general community, of which 66 completed all visits. Mean age of participants was 49.3 ▒ 6.3 years and mean body mass index was 33.7 ▒ 3.6 kg/m(2).
INTERVENTION:

elsewhere in bone mineral density in obese men

Oral treatment with 1.000 mg RSV (RSV(high)), 150 mg RSV (RSV(low)), or placebo daily for 16 weeks.
MAIN OUTCOME MEASURE:

Prespecified primary endpoint was change in bone alkaline phosphatase (BAP).

RESULTS:

BAP increased dose dependently with RSV (R = 0.471, P < .001), resulting in a significantly greater increase in BAP in the RSV(high) group compared with placebo at all time-points (week 4, 16.4 ▒ 4.2%, P < .001; week 8, 16.5 ▒ 4.1%, P < .001; week 16, 15.2 ▒ 3.7%, P < .001). Lumbar spine trabecular volumetric bone mineral density (LS vBMD(trab)) also increased dose dependently with RSV (R = 0.268, P = .036), with a significant increase of 2.6 ▒ 1.3% in the RSV(high) group compared with placebo (P = .043). In addition, changes in BAP and LS vBMD(trab) were positively correlated (R = 0.281, P = .027).

No consistent changes were detected in bone density at the hip.
CONCLUSIONS:

Our data suggest that high-dose RSV supplementation positively affects bone, primarily by stimulating formation or mineralization. Future studies of longer duration comprising populations at risk of osteoporosis are needed to confirm these results.
TRIAL REGISTRATION:

ClinicalTrials.gov NCT01412645.

PMID:
25322274
[PubMed - indexed for MEDLINE]

Reply to this post

Back to OP Alert abuse Link to post in-thread

Always highlight: 10 newest replies | Replies posted after I mark a forum
Replies to this discussion thread
Please login to view edit histories.